Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,8308082,flow-rate,"Analytes are measured after extraction of alkalinised urine with diethyl ether and subsequent back extraction with 0.5 M H2SO4 and with chromatography performed on a reversed-phase C18 column, using a mobile phase of acetonitrile-50 mM K2HPO4 (25:75, v/v) (flow-rate 1.3 ml/min) and ultraviolet detection at 210 nm.",Determination of dexfenfluramine and nordexfenfluramine in urine by high-performance liquid chromatography using ultraviolet detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8308082/),[ml] / [min],1.3,5334,DB01191,Dexfenfluramine
,8308082,sensitivity,The sensitivity of the technique (10 ng/ml) is appropriate to measure both parent drug and metabolite in urine in humans for up to 5 days after a single 30-mg dose.,Determination of dexfenfluramine and nordexfenfluramine in urine by high-performance liquid chromatography using ultraviolet detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8308082/),[ng] / [ml],10,5335,DB01191,Dexfenfluramine
,7654489,volume of distribution (Vss),"After i.v. infusion in obese subjects, the volume of distribution (Vss) of d-F was significantly higher (969.7 +/- 393.3 l; 95% CI 688.6-1250 l) than in controls (668.7 +/- 139.6 l; 95% CI 568.9-768.5 l; P < 0.01).",The pharmacokinetics of dexfenfluramine in obese and non-obese subjects. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7654489/),l,969.7,46058,DB01191,Dexfenfluramine
,7654489,volume of distribution (Vss),"After i.v. infusion in obese subjects, the volume of distribution (Vss) of d-F was significantly higher (969.7 +/- 393.3 l; 95% CI 688.6-1250 l) than in controls (668.7 +/- 139.6 l; 95% CI 568.9-768.5 l; P < 0.01).",The pharmacokinetics of dexfenfluramine in obese and non-obese subjects. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7654489/),l,668.7,46059,DB01191,Dexfenfluramine
,7654489,Clearance,Clearance was not significantly different (43.9 +/- 21.0 l h-1 vs 37.3 +/- 10.6 l h-1) and the terminal half-life tended to be longer (17.8 +/- 9.4 vs 13.5 +/- 3.9 h NS).,The pharmacokinetics of dexfenfluramine in obese and non-obese subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7654489/),[l] / [h],43.9,46060,DB01191,Dexfenfluramine
,7654489,Clearance,Clearance was not significantly different (43.9 +/- 21.0 l h-1 vs 37.3 +/- 10.6 l h-1) and the terminal half-life tended to be longer (17.8 +/- 9.4 vs 13.5 +/- 3.9 h NS).,The pharmacokinetics of dexfenfluramine in obese and non-obese subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7654489/),[l] / [h],37.3,46061,DB01191,Dexfenfluramine
,7654489,terminal half-life,Clearance was not significantly different (43.9 +/- 21.0 l h-1 vs 37.3 +/- 10.6 l h-1) and the terminal half-life tended to be longer (17.8 +/- 9.4 vs 13.5 +/- 3.9 h NS).,The pharmacokinetics of dexfenfluramine in obese and non-obese subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7654489/),h,17.8,46062,DB01191,Dexfenfluramine
,7654489,terminal half-life,Clearance was not significantly different (43.9 +/- 21.0 l h-1 vs 37.3 +/- 10.6 l h-1) and the terminal half-life tended to be longer (17.8 +/- 9.4 vs 13.5 +/- 3.9 h NS).,The pharmacokinetics of dexfenfluramine in obese and non-obese subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7654489/),h,13.5,46063,DB01191,Dexfenfluramine
,7654489,oral bioavailability,The oral bioavailability of d-F was 0.61 +/- 0.15 in obese subjects and 0.69 +/- 0.11 in controls.,The pharmacokinetics of dexfenfluramine in obese and non-obese subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7654489/),,0.61,46064,DB01191,Dexfenfluramine
,7654489,oral bioavailability,The oral bioavailability of d-F was 0.61 +/- 0.15 in obese subjects and 0.69 +/- 0.11 in controls.,The pharmacokinetics of dexfenfluramine in obese and non-obese subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7654489/),,0.69,46065,DB01191,Dexfenfluramine
,7654489,Cmax,"There was no significant difference between obese subjects and controls in Cmax, tmax and t1/2,z (Cmax: 20.1 +/- 6.7 and 27.3 +/- 6.2 micrograms l-1; tmax: 3.5 vs 3.0; t1/2,z: 16.5 +/- 7.1 vs 14.5 +/- 2.6 h respectively).",The pharmacokinetics of dexfenfluramine in obese and non-obese subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7654489/),[μg] / [l],20.1,46066,DB01191,Dexfenfluramine
,7654489,Cmax,"There was no significant difference between obese subjects and controls in Cmax, tmax and t1/2,z (Cmax: 20.1 +/- 6.7 and 27.3 +/- 6.2 micrograms l-1; tmax: 3.5 vs 3.0; t1/2,z: 16.5 +/- 7.1 vs 14.5 +/- 2.6 h respectively).",The pharmacokinetics of dexfenfluramine in obese and non-obese subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7654489/),[μg] / [l],27.3,46067,DB01191,Dexfenfluramine
,7654489,tmax,"There was no significant difference between obese subjects and controls in Cmax, tmax and t1/2,z (Cmax: 20.1 +/- 6.7 and 27.3 +/- 6.2 micrograms l-1; tmax: 3.5 vs 3.0; t1/2,z: 16.5 +/- 7.1 vs 14.5 +/- 2.6 h respectively).",The pharmacokinetics of dexfenfluramine in obese and non-obese subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7654489/),,3.5,46068,DB01191,Dexfenfluramine
,7654489,tmax,"There was no significant difference between obese subjects and controls in Cmax, tmax and t1/2,z (Cmax: 20.1 +/- 6.7 and 27.3 +/- 6.2 micrograms l-1; tmax: 3.5 vs 3.0; t1/2,z: 16.5 +/- 7.1 vs 14.5 +/- 2.6 h respectively).",The pharmacokinetics of dexfenfluramine in obese and non-obese subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7654489/),h,3.0,46069,DB01191,Dexfenfluramine
,7654489,"t1/2,z","There was no significant difference between obese subjects and controls in Cmax, tmax and t1/2,z (Cmax: 20.1 +/- 6.7 and 27.3 +/- 6.2 micrograms l-1; tmax: 3.5 vs 3.0; t1/2,z: 16.5 +/- 7.1 vs 14.5 +/- 2.6 h respectively).",The pharmacokinetics of dexfenfluramine in obese and non-obese subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7654489/),h,16.5,46070,DB01191,Dexfenfluramine
,7654489,"t1/2,z","There was no significant difference between obese subjects and controls in Cmax, tmax and t1/2,z (Cmax: 20.1 +/- 6.7 and 27.3 +/- 6.2 micrograms l-1; tmax: 3.5 vs 3.0; t1/2,z: 16.5 +/- 7.1 vs 14.5 +/- 2.6 h respectively).",The pharmacokinetics of dexfenfluramine in obese and non-obese subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7654489/),h,14.5,46071,DB01191,Dexfenfluramine
,7654489,AUC ratio,The AUC ratio expressed in molar units for d-F/d-NF was 2.29 +/- 1.78 (i.v.) vs 1.25 +/- 0.64 (oral) in obese subjects and 2.05 +/- 1.26 (i.v.) vs 1.40 +/- 0.87 (oral) in controls.,The pharmacokinetics of dexfenfluramine in obese and non-obese subjects. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7654489/),,2.29,46072,DB01191,Dexfenfluramine
,7654489,AUC ratio,The AUC ratio expressed in molar units for d-F/d-NF was 2.29 +/- 1.78 (i.v.) vs 1.25 +/- 0.64 (oral) in obese subjects and 2.05 +/- 1.26 (i.v.) vs 1.40 +/- 0.87 (oral) in controls.,The pharmacokinetics of dexfenfluramine in obese and non-obese subjects. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7654489/),,1.25,46073,DB01191,Dexfenfluramine
,7654489,AUC ratio,The AUC ratio expressed in molar units for d-F/d-NF was 2.29 +/- 1.78 (i.v.) vs 1.25 +/- 0.64 (oral) in obese subjects and 2.05 +/- 1.26 (i.v.) vs 1.40 +/- 0.87 (oral) in controls.,The pharmacokinetics of dexfenfluramine in obese and non-obese subjects. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7654489/),,2.05,46074,DB01191,Dexfenfluramine
,7654489,AUC ratio,The AUC ratio expressed in molar units for d-F/d-NF was 2.29 +/- 1.78 (i.v.) vs 1.25 +/- 0.64 (oral) in obese subjects and 2.05 +/- 1.26 (i.v.) vs 1.40 +/- 0.87 (oral) in controls.,The pharmacokinetics of dexfenfluramine in obese and non-obese subjects. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7654489/),,1.40,46075,DB01191,Dexfenfluramine
,8578770,maximum plasma levels (Cmax),"2. The drug was rapidly N-deethylated to dexnorfenfluramine achieving comparatively low mean maximum plasma levels (Cmax) of 12-14 ng/ml in all primates, and rapidly disappeared thereafter with half-lives (t1/2) ranging from 2 to 3 h in the baboon and rhesus monkey to 6 h in the cynomolgus monkey.",Oral kinetics of dexfenfluramine and dexnorfenfluramine in non-human primates. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8578770/),[ng] / [ml],12-14,62140,DB01191,Dexfenfluramine
,8578770,half-lives (t1/2),"2. The drug was rapidly N-deethylated to dexnorfenfluramine achieving comparatively low mean maximum plasma levels (Cmax) of 12-14 ng/ml in all primates, and rapidly disappeared thereafter with half-lives (t1/2) ranging from 2 to 3 h in the baboon and rhesus monkey to 6 h in the cynomolgus monkey.",Oral kinetics of dexfenfluramine and dexnorfenfluramine in non-human primates. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8578770/),h,2 to 3,62141,DB01191,Dexfenfluramine
,8578770,half-lives (t1/2),"2. The drug was rapidly N-deethylated to dexnorfenfluramine achieving comparatively low mean maximum plasma levels (Cmax) of 12-14 ng/ml in all primates, and rapidly disappeared thereafter with half-lives (t1/2) ranging from 2 to 3 h in the baboon and rhesus monkey to 6 h in the cynomolgus monkey.",Oral kinetics of dexfenfluramine and dexnorfenfluramine in non-human primates. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8578770/),h,6,62142,DB01191,Dexfenfluramine
,8578770,Cmax,"Its normetabolite reached higher mean Cmax (52-97 ng/ml) and the t1/2's were longer, varying from about 11 h in the rhesus monkey to 22 h in the cynomolgus monkey.",Oral kinetics of dexfenfluramine and dexnorfenfluramine in non-human primates. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8578770/),[ng] / [ml],52-97,62143,DB01191,Dexfenfluramine
,8578770,t1/2's,"Its normetabolite reached higher mean Cmax (52-97 ng/ml) and the t1/2's were longer, varying from about 11 h in the rhesus monkey to 22 h in the cynomolgus monkey.",Oral kinetics of dexfenfluramine and dexnorfenfluramine in non-human primates. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8578770/),h,11,62144,DB01191,Dexfenfluramine
,8578770,t1/2's,"Its normetabolite reached higher mean Cmax (52-97 ng/ml) and the t1/2's were longer, varying from about 11 h in the rhesus monkey to 22 h in the cynomolgus monkey.",Oral kinetics of dexfenfluramine and dexnorfenfluramine in non-human primates. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8578770/),h,22,62145,DB01191,Dexfenfluramine
,10407087,steady-state brain concentration,The steady-state brain concentration averaged approximately 4 microM and did not tend to increase significantly during the 90 day treatment period.,Measurement of human brain dexfenfluramine concentration by 19F magnetic resonance spectroscopy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10407087/),μM,4,91789,DB01191,Dexfenfluramine
